Dyadic International

What Dyadic International does

Dyadic International, operating commercially as Dyadic Applied BioSolutions, is a global industrial biotechnology company that develops and commercializes recombinant proteins using two proprietary microbial expression platforms: C1 and Dapibus™, both based on the filamentous fungal host Thermothelomyces heterothallica discovered in the 1990s. The company serves three end markets — Life Sciences (recombinant human proteins for research, diagnostics, and bioprocessing), Food & Nutrition (animal-free proteins such as lactoferrin, bovine alpha-lactalbumin, and dairy enzymes for infant formula and functional foods), and Bio-Industrial (cellulase, beta-glucanase, xylanase, and pulp & paper enzyme cocktails). The platforms have been validated at >100,000L fermentation scale, hold GRAS designation for food-grade applications, support cGMP manufacturing, and have completed a first-in-human Phase I study. Per the company, the C1 platform can progress from a codon-optimized gene sequence to purified antigen or monoclonal antibody in approximately 15 days — a key speed claim vs. mammalian-cell alternatives.

Revenue is generated through four streams: direct product sales of recombinant proteins (e.g., AlbuFree™ DX human albumin with Proliant Health & Biologicals, DNase I with Fermbox Bio); license and milestone payments from partners manufacturing in-house (IBT Bioservices, Fermbox, Proliant); custom R&D services (strain engineering and process development); and grant funding from global health organizations (Gates Foundation, CEPI). Distribution combines direct enterprise sales, technology licensing, partner-led commercialization, and co-development arrangements. The company operates globally with headquarters in Jupiter, Florida and active partnerships spanning North America, Europe, India, Japan, and South Korea. Founded in 1979 by Mark A. Emalfarb (current CEO), the company is publicly traded on NASDAQ (DYAI) and rebranded in 2025 to reflect its pivot from a development-stage platform to a product-driven commercial entity. FY 2025 revenue was approximately $3.09M with a $7.36M net loss, and the company received a Nasdaq minimum bid price deficiency notice in December 2025.

Name

Dyadic International

Legal name

Dyadic International, Inc.

Website

https://dyadic.com

Company type

Public

Founded year

1979

Operating status

Operating

Headcount range

51–100 employees

Short description

Dyadic International (Dyadic Applied BioSolutions) is a publicly traded industrial biotechnology company that uses its proprietary C1 and Dapibus™ filamentous fungal platforms to produce and license recombinant proteins for life sciences, food & nutrition, and bio-industrial customers globally.

Ownership category

akta.pro rank

Product category

Industrial Biotechnology / Recombinant Protein Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Food Manufacturing (311)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Food And Kindred Products (2000)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

akta.pro secondary industries

Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins) (AFAJAHAL), Microbial Coagulants & Fermentation-Derived Enzymes (Chymosin, Microbial Rennet Systems) (AFAJAJAJ), Mycoprotein & Fungal Proteins (Fusarium/Mycelium-Based) (AFAJAHAE)

Keywords

• Recombinant protein production
• Microbial expression platforms
• Industrial biotechnology enzymes
• Precision fermentation proteins
• Animal-free biomanufacturing

Headquarters

HQ city

Jupiter

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Product Sales: Recurring revenue from product sales of recombinant proteins including research-grade proteins, GMP-grade materials, and commercial proteins for diagnostics, cell culture, and bioprocessing applications. Revenue increased 182% year-over-year to $1.11M in Q1 2026 driven by increases in R&D revenue and product launches.
2. License and Milestone Revenue: License fees and milestone payments from partners licensing C1 or Dapibus™ platforms for in-house manufacturing. Partners include Proliant Health & Biologicals, IBT Bioservices, and Fermbox Bio arrangements.
3. Research and Development Services: Custom strain engineering, technology transfer, and process development services. Revenue categorized as 'research and development revenue' in financial statements at $403,590 in Q1 2026.
4. Grant Revenue: Grant funding from global health organizations including CEPI and Gates Foundation for pandemic preparedness and infectious disease research. Grant revenue was $487,366 in Q1 2026.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Dyadic International (doing business as Dyadic Applied BioSolutions) develops and manufactures recombinant proteins and enzymes using its proprietary C1 and Dapibus™ filamentous fungal microbial expression platforms. The company sells commercial-grade proteins for life sciences (e.g., AlbuFree™ DX recombinant human albumin, DNase I, transferrin, FGF, alpha-lactalbumin), animal-free food proteins (lactoferrin, bovine alpha-lactalbumin, dairy enzymes), and industrial enzyme cocktails (cellulase, xylanase, pulp & paper enzymes). Revenue is generated through direct product sales, technology licensing, custom strain development services, and grant-funded research collaborations with global health organizations.

Product overview

Dyadic Applied BioSolutions operates as a platform company with two proprietary microbial expression systems—C1 and Dapibus™—that serve as the foundation for a growing portfolio of commercial recombinant proteins and enzymes. The C1 platform is production-proven at commercial scale with Phase I clinical validation, while the Dapibus platform is optimized for yield and cost in food, nutrition, and industrial applications. The company's product portfolio spans three market segments: Life Sciences (recombinant human proteins including AlbuFree DX albumin, DNase I, transferrin, FGF, and alpha-lactalbumin for research, diagnostics, and bioprocessing); Food & Nutrition (animal-free proteins including lactoferrin, bovine alpha-lactalbumin, bovine FGF, bovine transferrin, and dairy enzymes for functional foods, infant formula, and cultured meat); and Bio-Industrial (enzyme cocktails including cellulase complexes, beta-glucanase, xylanase, and pulp & paper enzymes for biofuels, textiles, and specialty chemicals). The platforms enable flexible, scalable, animal-free protein production from lab to commercial scale (>100,000 liters).

Differentiator

Problem solved

Functional benefit

Brands

• AlbuFree DX: Recombinant human albumin product commercialized with Proliant Health & Biologicals for research, diagnostic, and cell culture applications
• C1 Platform
• Dapibus Platform

Products and services

• AlbuFree™ DX Recombinant Human Albumin Recombinant human albumin produced via the C1 microbial platform for research, diagnostic, and cell culture applications, offering an animal-free, scalable alternative to plasma-derived albumin. Commercialized with Proliant Health & Biologicals.
• Animal-Origin-Free Recombinant DNase I (RNase-Free) Animal-origin-free recombinant DNase I enzyme for RNA workflows in diagnostics and gene therapy manufacturing, enabling removal of genomic DNA from RNA samples. Co-developed and commercialized with Fermbox Bio.
• Recombinant Human Transferrin Recombinant human transferrin for research, diagnostic, and cell culture media applications, providing iron transport functionality without animal-derived components.
• Recombinant Human FGF (Fibroblast Growth Factor) Recombinant human fibroblast growth factor for research, diagnostic, and cell culture media applications supporting cell growth and metabolism.
• Recombinant Human Alpha-Lactalbumin Recombinant human alpha-lactalbumin for research, diagnostic, and cell culture media applications, designed as nutritional whey protein for infant formula, medical, and wellness applications.
• Recombinant Human Lactoferrin Recombinant human lactoferrin for premium and functional nutrition applications, providing immune-supportive protein properties produced via microbial fermentation.
• Recombinant Bovine Alpha-Lactalbumin Recombinant bovine alpha-lactalbumin for infant formula, functional foods, and wellness applications, enabling animal-free dairy protein production. Developed under partnership with BRIG Bio.
• Recombinant Bovine FGF Recombinant bovine fibroblast growth factor for food, nutrition, and cultured meat applications, supporting cell growth and metabolism in bioprocessing.
• Recombinant Bovine Transferrin Recombinant bovine transferrin for food, nutrition, and cultured meat applications, providing iron-binding protein functionality for cell culture and nutrition.
• Non-Animal Dairy Enzymes High-performance enzymes for cheese and dairy processing workflows produced via microbial fermentation, replacing animal-derived enzyme sources.
• Pulp & Paper Enzyme Cocktail Industrial-grade glycolytic enzyme blend for pulp & paper and biomass conversion applications, enabling efficient enzymatic processing of lignocellulosic materials.
• Cellulase Enzyme Complexes Enzyme blends supporting cellulose degradation and fiber modification in industrial applications including biofuels and textile processing.
• Beta-Glucanase and Xylanase Enzymes Enzymes improving viscosity reduction, yield, and clarity in brewing and food processing applications through targeted polysaccharide hydrolysis.
• Cellulosic Enzyme Cocktail (Fermbox Partnership) Custom enzyme formulation developed with Fermbox partnership for biomass degradation and cellulosic ethanol production, enabling sustainable biofuel manufacturing.
• C1 Protein Production Platform Production-proven filamentous fungal expression platform using Thermothelomyces heterothallica, validated at commercial scale exceeding 100,000 liters, with Phase I clinical validation and cGMP capability. Used for complex protein production with high yield and low cost; can progress from gene sequence to purified antigen or monoclonal antibody in approximately 15 days. Licensed to partners and used for in-house manufacturing of recombinant proteins.
• Dapibus™ Expression System Yield and cost-optimized microbial expression platform for high-volume protein production in food, nutrition, and industrial applications, featuring sustainable, low-cost manufacturing via low-carbon precision fermentation and animal-free production. Licensed to partners such as Fermbox Bio and Inzymes.
• C1 HCP ELISA Test ELISA-based quality assurance test for detecting host cell proteins (HCP) in biomanufacturing processes using Dyadic's C1 platform, co-developed with Cygnus Technologies.

Quantifiable outcome

• C1 platform progresses from gene sequence to purified antigen or monoclonal antibody in approximately 15 days
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development Partner · 15 June 2026Research proposals submitted to CEPI's Ebola funding call as part of Dyadic's pandemic preparedness activities. CEPI funding would support development of rapid response manufacturing capabilities for Ebola and other infectious diseases using the C1 platform.
• Fondazione Biotecnopolo di Siena and European Vaccines HubcoreStrategic or Co-development Partner · 15 June 2026Monoclonal antibody initiative targeting Ebola and other infectious disease threats. Collaboration with European Vaccines Hub for rapid development and manufacturing of antibody therapeutics using Dyadic's C1 platform.
• Scripps ResearchcoreStrategic or Co-development Partner · 28 May 2026Collaboration to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus which causes Hantavirus Pulmonary Syndrome. Partnership leverages Dyadic's proprietary C1 microbial protein production platform combined with Scripps Research's structure-based protein design expertise for rapid, scalable biologic manufacturing for pandemic preparedness. Builds on prior Andes virus antibody work and prior collaborations on Marburg and Ebola viruses.
• IBT BioservicesmajorChannel Partner/ Reseller/ Distributor · 16 March 2026OEM distribution agreement for Dyadic's recombinant proteins and biologic manufacturing inputs. IBT Bioservices distributes Dyadic products as part of their biopharmaceutical service offerings.
• Fermbox BiocoreStrategic or Co-development Partner · 4 March 2026Expanded collaboration including commercial launch of animal-origin-free recombinant DNase I (RNase-Free) for RNA workflows in diagnostics and gene therapy. Partnership for custom enzyme formulations including cellulosic enzyme cocktail for biomass degradation and cellulosic ethanol production.
• InterlinkminorChannel Partner/ Reseller/ Distributor · 1 December 2025Asia-Pacific partnership for market expansion into Japan and South Korea. Enables broader geographic reach for Dyadic's products and platform technology in key Asian markets.
• Proliant Health & BiologicalscoreChannel Partner/ Reseller/ Distributor · 25 March 2025Commercial launch of AlbuFree™ DX recombinant human albumin using Dyadic's production platform. Dyadic eligible to receive a share of profits from product sales. Product for research, diagnostic, and cell culture applications.
• BRIG BiomajorStrategic or Co-development Partner · 25 March 2025Development agreement for recombinant bovine alpha-lactalbumin for infant formula, functional foods, and wellness applications. Dyadic to build proprietary strain for partner IP.
• VTT Technical Research Centre of FinlandminorStrategic or Co-development PartnerResearch and development partnership for enzyme and protein development applications. VTT logo appears on Dyadic's partners page indicating active collaboration.
• InzymesminorChannel Partner/ Reseller/ DistributorStrategic partnership for enzyme products and bio-industrial applications. Inzymes logo appears on Dyadic's partners page indicating active collaboration.
• RubicminorStrategic or Co-development PartnerPartnership for protein development and commercialization. Rubic logo appears on Dyadic's partners page indicating active collaboration.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Perfect Day: Precision fermentation company producing animal-free whey proteins for food applications. Directly comparable to Dyadic's Dapibus platform and food/nutrition segment targeting recombinant alpha-lactalbumin, lactoferrin, and other dairy proteins via microbial fermentation.
• Codexis: Engineered enzymes and biocatalysts company using proprietary protein engineering platforms for pharmaceutical and industrial applications. Closely comparable to Dyadic's protein engineering and platform-licensing model, including a similar mixture of licensing revenue and direct product sales.
• AB Enzymes: Specialty industrial enzyme manufacturer serving food, beverage, and industrial processing markets. Closely comparable to Dyadic's bio-industrial enzyme portfolio (cellulases, xylanases, beta-glucanases) and its food/nutrition dairy enzymes.

Broad incumbents

• Novonesis (formerly Novozymes): Global leader in industrial enzymes and microbial protein production with deep fermentation expertise. Directly comparable to Dyadic's bio-industrial enzyme segment and to the broader Dapibus platform thesis, though Novonesis operates at vastly greater scale and across many more end markets.
• International Flavors & Fragrances (IFF): Diversified ingredients company with a major Health & Biosciences division producing enzymes, cultures, and fermentation-derived proteins. Comparable to Dyadic's bio-industrial enzyme offering and a potential large customer for the Dapibus platform in food and industrial markets.
• Sartorius AG: Bioprocessing solutions provider serving biopharmaceutical manufacturers with cell lines, fermentation technologies, and process equipment. Comparable to the broader C1 platform ecosystem where Dyadic competes for biopharma manufacturing partnerships.
• GenScript Biotech: Life sciences tools and biopharmaceutical services company with proprietary recombinant protein production and biologics manufacturing capabilities. Comparable as a competitor/supplier in the life sciences segment where Dyadic sells research-grade proteins and biologics inputs.
• Ginkgo Bioworks: Synthetic biology platform company engineering microbial strains for industrial applications across food, industrial enzymes, and biopharma. Closely comparable to Dyadic's C1 and Dapibus platform thesis of using proprietary microbial hosts for protein production at scale.
• DSM-Firmenich: Global nutrition, health, and bioscience company with significant precision fermentation and enzyme capabilities. Comparable as a large incumbent partner/customer profile for Dyadic's food, nutrition, and industrial enzyme segments.

Emerging players

• The EVERY Company (formerly Clara Foods): Precision fermentation company producing animal-free proteins such as ovalbumin and dairy proteins using microbial expression. Directly comparable to Dyadic's food and nutrition segment and alternative-protein commercialization model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/DyadicIntl
• LinkedInlinkedin.com/company/dyadic-international-inc.
• Xx.com/dyadic_intl

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds10 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dyadic International